Tirzepatide (Mounjaro) | Shankar IAS Academy | UPSC current Affairs

Опубликовано: 30 Март 2025
на канале: Shankar IAS Academy

307

FOR PDF CHECK: https://www.shankariasparliament.com/...

1. Tirzepatide (Mounjaro): A Game-Changer for Diabetes & Obesity in India? | UPSC Mains Biotech | GLP-1 & GIP

Explore the groundbreaking launch of Tirzepatide (Mounjaro) in India, a new drug targeting both type 2 diabetes and chronic obesity. This video delves into the working mechanism of Tirzepatide, its dual action on GLP-1 and GIP receptors, and its comparison with Ozempic (Semaglutide). We discuss its potential impact on India's rising diabetes and obesity rates, as highlighted by recent surveys and projections. Understand its features, side effects, and significance for UPSC Mains Biotechnology and Current Affairs.

Visit our website - https://www.shankariasacademy.com/ups...
Facebook -   / shankariasacademy
Instagram -   / shankariasacademy
Twitter -   / shankarias
For UPSC & TNPSC books - https://www.siabookmark.com/
Monthly current affairs - https://www.shankariasparliament.com/...

#UPSC #CSE #CurrentAffairs #dailycurrentaffairs #currentaffairs #DailyNewsAnalysis #NewsAnalysis #TheHindu #EditorialAnalysis #Exams #thehinduanalysis #hinduanalysis #hinduupsc #hinduias #hindunewspaperanalysisforupsc #upscpre2025 #upsccseprelims2025 #todaycurrentaffairs #currentaffairsforupsc #todaynewsupdates #currentaffairstoday #iasprep #iasprelims #ias #upsccseprelims #iasprelims2025 #upsc2025 #currentaffairs2025 #shankariasacademy #March #2025 #UPSC
#IAS
#CivilServices
#Biotechnology
#Diabetes
#Obesity
#Tirzepatide
#Mounjaro
#GLP1
#GIP
#Ozempic
#Semaglutide
#CDSCO
#CurrentAffairs
#IndiaHealth
#ScienceAndTechnology
#DrugRegulation
#HealthcareIndia